MET-097i: Molecular Structure
Chemical properties, amino acid sequence, and structural analysis
📌TL;DR
- •Molecular formula: Proprietary (not publicly disclosed)
- •Molecular weight: 4500 Da
- •Half-life: Approximately 380 hours (~16 days)
Amino Acid Sequence
66 amino acids
Formula
Proprietary (not publicly disclosed)
Molecular Weight
4500 Da
Half-Life
Approximately 380 hours (~16 days)
Molecular Structure#
MET-097i consists of a GLP-1 receptor agonist peptide linked to a proprietary oligomeric carrier using the HALO platform. The exact peptide sequence and oligomer structure have not been publicly disclosed. The construct is designed for subcutaneous administration with slow, sustained release.
HALO Platform#
| Feature | Description |
|---|---|
| Technology | Half-life Augmented Linker and Oligomer |
| Components | GLP-1 peptide + proprietary linker + oligomeric carrier |
| Half-life extension | ~380 hours (vs ~165 hours for semaglutide) |
| Dosing frequency | Once monthly |
| Modularity | Platform applicable to other peptide targets |
Biased Agonism#
MET-097i is characterized as a biased GLP-1 agonist, preferentially activating G-protein-coupled signaling over beta-arrestin recruitment. This signaling bias may result in reduced receptor internalization and potentially fewer gastrointestinal side effects while maintaining efficacy.
| Signaling Pathway | Activity |
|---|---|
| G-protein (cAMP) | Full agonism |
| Beta-arrestin | Reduced activity (biased) |
| Receptor internalization | Potentially reduced |
Pharmacokinetic Properties#
| Parameter | Value |
|---|---|
| Half-life | ~380 hours (~16 days) |
| Administration | Subcutaneous injection |
| Dosing frequency | Once monthly (target) |
| Steady state | Expected within 2-3 months |
| Tmax | Slow absorption from SC depot |
Comparison with Other GLP-1 Agonists#
| Property | MET-097i | Semaglutide | Liraglutide |
|---|---|---|---|
| Half-life | ~380 hours | ~165 hours | ~13 hours |
| Dosing | Monthly | Weekly | Daily |
| Signaling bias | G-protein biased | Balanced | Balanced |
| Technology | HALO conjugate | Fatty acid acylation | Fatty acid acylation |
Molecular Context#
MET-097i belongs to the Metabolic category of research peptides. The molecular properties of MET-097i determine its pharmacological behavior, including receptor binding, distribution, metabolism, and elimination. Understanding these properties is fundamental to interpreting clinical data and designing research protocols.
Structural Overview#
MET-097i is characterized as: MET-097i is a GLP-1 receptor agonist peptide conjugated to a proprietary oligomeric carrier via the HALO (Half-life Augmented Linker and Oligomer) platform. The conjugation dramatically extends the half-life to approximately 380 hours, enabling once-monthly subcutaneous dosing. The molecule is a biased GLP-1 agonist, preferentially activating G-protein signaling over beta-arrestin pathways..
Amino Acid Sequence Details#
The amino acid sequence of MET-097i is: Not publicly disclosed (GLP-1 peptide conjugated to HALO oligomer). This sequence determines the peptide's three-dimensional structure, receptor binding properties, and biological activity.
Pharmacokinetic Profile#
Half-Life: Approximately 380 hours (~16 days)
The half-life of a peptide influences dosing frequency, duration of effect, and the clinical utility of the compound. Researchers should consider the half-life when designing experimental protocols.
Related Reading#
Frequently Asked Questions About MET-097i
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer